Persistence of antibodies 3 years after booster vaccination of adults with combined acellular pertussis, diphtheria and tetanus toxoids vaccine

Vaccine

Volumn 29, Issue 47, 2011, Pages 8483-8486

  Weston, Wayde ^a   Messier, Marc ^b   Friedland, Leonard R ^a   Wu, Xiangfeng ^a   Howe, Barbara ^a  

^a GLAXOSMITHKLINE   (United States)

^b GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

Author keywords

Acellular pertussis; Diphtheria and tetanus toxoids vaccine; Vaccine, persistence

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS VACCINE;

ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ARTICLE; DIPHTHERIA; FEMALE; FOLLOW UP; HUMAN; HUMORAL IMMUNITY; IMMUNOGENICITY; MAJOR CLINICAL STUDY; MALE; PERTUSSIS; PRIORITY JOURNAL; TETANUS; VACCINATION;

ADULT; ANTIBODIES, BACTERIAL; ANTITOXINS; DIPHTHERIA-TETANUS-ACELLULAR PERTUSSIS VACCINES; DIPHTHERIA-TETANUS-PERTUSSIS VACCINE; HUMANS; IMMUNIZATION, SECONDARY; TIME FACTORS;

EID: 82455192357     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.09.063     Document Type: Article

References (10)

1. Centers for Disease Control and Prevention Notice to readers: final 2009 Reports of Nationally Notifiable Infectious Diseases. MMWR 2010, 59:1025-1039.
2. Cherry J.D. The epidemiology of pertussis: a comparison of the epidemiology of the disease pertussis with the epidemiology of Bordetella pertussis infection. Pediatrics 2005, 115:1422-1427.
3. California Department of Public Health Pertussis report 2011, [Accessed 06-05-2011] Available from: http://www.cdph.ca.gov/programs/immunize/Documents/PertussisReport2011-01-07.pdf.
4. Weston W.M., Friedland L.R., Wu S., Howe B. Vaccination of adults 65 years of age and older with tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Boostrix™): results of a randomized clinical trial. 45th National Immunization Conference, March 28-31, 2011 2011.
5. Blatter M., Friedland L.R., Weston W.M., Li P., Howe B. Immunogenicity and safety of a tetanus toxoid, reduced diphtheria toxoid and three-component acellular pertussis vaccine in adults 19-64 years of age. Vaccine 2009, 27:765-772.
6. General recommendations on immunization-recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Surveill Summ 2011, 60:1-64.
7. Booy R., Van der Meeren O., Ng S.-P., Celzo F., Ramakrishnan G., Jacquet J.-M. A decennial booster dose of reduced antigen content diphtheria, tetanus, acellular pertussis vaccine (Boostrix™) is immunogenic and well tolerated in adults. Vaccine 2010, 29:45-50.
8. Turnbull F.M., Heath T.C., Jalaludin B.B., Burgess M.A., Ramalho A.C. A randomized trial of two acellular pertussis vaccines (dTpa and pa) and a licensed diphtheria-tetanus vaccine (Td) in adults. Vaccine 2000, 19:628-636.
9. Edelman K., He Q., Mäkinen J., Sahlberg A., Haanperä M., Schuerman L., et al. Immunity to pertussis 5 years after booster immunization during adolescence. Clin Infect Dis 2007, 44:1271-1277.
10. Mertsola J., Van Der Meeren O., He Q., Linko-Parvinen A., Ramakrishnan G., Mannermaa L., et al. Decennial administration of a reduced antigen content diphtheria and tetanus toxoids and acellular pertussis vaccine in young adults. Clin Infect Dis 2010, 51:656-662.